Please assess the completion status of the following clinical trial:

Trial Title: Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• Osteoporosis as defined by very low bone mineral density in the hip and spine or low bone mineral density in the hip combined with presence of 1-3 mild or moderate fractures of the vertebrae~Exclusion Criteria:~* Low Vitamin D~* Renal insufficiency~* Previous treatment with certain anti-osteoporotic therapies (except after certain washout periods): calcitonin, bisphosphonates, parathyroid hormone (PTH), sodium fluoride, strontium ranelate,~* Previous treatment with testosterone, anabolic steroids or growth hormone~* Chronic use of systemic corticosteroids (oral or i.v.) within the last year~* History of any cancer or metastases within the last 5 years~* History of brittle bone disease, multiple myeloma, or Paget's disease, or any other metabolic bone disease, except osteoporosis~* Bilateral hip replacements~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid (Type: EXPERIMENTAL): 5 mg/100 ml administered via a peripheral intravenous site as a slow infusion over 15 minutes. The intravenous (i.v.) infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.
- Placebo (Type: PLACEBO_COMPARATOR): 100 ml Placebo administered via a peripheral intravenous site as a slow infusion over 15 minutes. The i.v. infusion was delivered via vented infusion line (to allow constant flow) and 20-22 gauge angiocatheter, and preceded and followed by a 10 ml normal saline flush of the intravenous line for a total volume infused of 120 ml once a year.

Based on this trial design, predict the completion outcome and termination type (if applicable).